表紙
市場調査レポート

膠芽腫治療薬の世界市場:2015年〜2019年

Global Glioblastoma Multiforme Therapeutics Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 336496
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
膠芽腫治療薬の世界市場:2015年〜2019年 Global Glioblastoma Multiforme Therapeutics Market 2015-2019
出版日: 2015年07月29日 ページ情報: 英文 81 Pages
概要

膠芽腫は最も悪性度が高い脳腫瘍のひとつで、致死率が高く、また、平均生存期間は1年程度と言われています。世界における膠芽腫治療薬市場は、2014年から2019年の間、11.94%のCAGRで拡大することが見込まれています。

当レポートでは、世界における膠芽腫治療薬市場の現況と今後の見通しを地域別に調査しており、主な市場の動向、成長要因と課題、主要ベンダーの分析などとともに提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 膠芽腫治療薬の世界市場
    • 市場概要
    • 市場規模と予測
  • ファイブフォース分析

第7章 薬剤投与経路別の市場分類

  • 経口
  • 非経口

第8章 分子タイプ別の市場分類

  • 小分子
  • 生物製剤

第9章 地理区分

  • 南北アメリカ
    • 市場概要
    • 市場規模と予測
  • 欧州・中東・アフリカ地域
    • 市場概要
    • 市場規模と予測
  • アジア太平洋地域
    • 市場概要
    • 市場規模と予測

第10章 購入基準

第11章 パイプラインのポートフォリオ

第12章 市場成長因子

第13章 成長因子とその影響

第14章 市場の課題

第15章 成長因子と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • Arbor Pharmaceuticals
    • Bristol-Myers Squibb
    • エーザイ
    • F. Hoffmann-La Roche
    • Merck
  • その他の今後有望なベンダー

第19章 主要ベンダーの分析

  • Arbor Pharmaceuticals
  • Bristol-Myers Squibb
  • エーザイ
  • F. Hoffmann-La Roche
  • Merck

第20章 関連レポート

目次
Product Code: IRTNTR6606

About Glioblastoma Multiforme

Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.

Glioblastoma multiforme is the most common variant of brain tumor, and highly invasive in nature. It may turn up in the cerebrum, mostly in the frontal and temporal lobes, and seldom spreads in areas outside the brain. The tumor progresses rapidly, and is among the most difficult-to-treat cancer with limited treatment options.

Glioblastoma multiforme is also known as Class IV astrocytoma which has an unknown etiology, and is more frequent in men than women. Some of the common symptoms of glioblastoma multiforme are increased intracranial pressure resulting in nausea, vomiting, and headache, cognitive and visual impairment, motor dysfunction, seizures, loss in sensory functions, and changes in personality, mood or concentration. The condition can be broadly classified into two types, primary or de novo glioblastoma multiforme (which progresses very fast) and secondary glioblastoma multiforme (which is known to progress at a slower rate). Glioblastoma multiforme can be treated by chemotherapy, steroids, radiation therapy, proton therapy, surgical procedure, and immunotherapies, which are the emerging treatment options yet to hit the market.

Technavio analysts forecast the global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme.

Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:

  • Oral
  • Parenteral

Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:

  • Small Molecules
  • Biologics

This report includes a discussion on the market in the following three regions:

  • The Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries, such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India

Technavio also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

The Technavio report, namely Global Glioblastoma Multiforme Therapeutics Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. The report covers the Americas, and EMEA and APAC markets. It presents the market landscape and its growth prospects in the coming years.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Arbor Pharmaceuticals
  • Bristol-Myers Squibb
  • Eisai
  • F. Hoffmann-La Roche
  • Merck

Other Prominent Vendors

  • AB Science
  • Abbvie
  • Actelion
  • Activartis Biotech
  • Advantagene
  • Agenus
  • Agios
  • Amgen
  • Angiochem
  • Apogenix
  • Axelar
  • BioNTech
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb
  • Celgene
  • Celldex Therapeutics
  • ChemoCentryx
  • Cortice Biosciences
  • CytoVac
  • CytRx
  • Deciphera
  • Del Mar Pharmaceuticals
  • Diffusion Pharmaceuticals
  • DNATrix
  • Eli Lilly
  • Epitopoietic Research
  • e-Therapeutics
  • Exelixis
  • G W Pharmaceuticals
  • Genspera
  • immatics
  • ImmunoCellular Therapeutics
  • Immunovaccine
  • Intrexon
  • IRAD Oncology
  • Karyopharm Therapeutics
  • Kite Pharma
  • Life Science Pharmaceuticals
  • Medicenna Therapeutics
  • Merck
  • Merrimack Pharmaceuticals
  • Nektar Therapeutics
  • Northwest Biotherapeutics
  • Novartis
  • Noxxon
  • OncoSynergy
  • Oncovir
  • Ono Pharmaceutical
  • Peregrine Pharmaceuticals
  • Plexxikon
  • Sanofi
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • Stemline Therapeutics
  • Tocagen
  • Tracon Pharma
  • TVAX Biomedical
  • VBL Therapeutics
  • Virttu Biologics
  • Ziopharm Oncology

Market Driver

  • Lack of Treatment Options for Glioblastoma Multiforme
  • For a full and detailed list, view our report

Market Challenge

  • Use of Off-label Drugs
  • For a full and detailed list, view our report

Market Trend

  • Prospective Entry of Novel Agents
  • For a full and detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Global Glioblastoma Multiforme Therapeutics Market
    • 06.1.1. Market Overview
    • 06.1.2. Market Size and Forecast
  • 06.2. Five Forces Analysis

07. Market Segmentation by Route of Administration

  • 07.1. Oral
  • 07.2. Parenteral

08. Market Segmentation by Type of Molecule

  • 08.1. Small Molecules
  • 08.2. Biologics

09. Geographical Segmentation

  • 09.1. Glioblastoma Multiforme Therapeutics Market in Americas
    • 09.1.1. Market Overview
    • 09.1.2. Market Size and Forecast
  • 09.2. Glioblastoma Multiforme Therapeutics Market in EMEA
    • 09.2.1. Market Overview
    • 09.2.2. Market Size and Forecast
  • 09.3. Glioblastoma Multiforme Therapeutics Market in APAC
    • 09.3.1. Market Overview
    • 09.3.2. Market Size and Forecast

10. Buying Criteria

11. Pipeline Portfolio

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. Arbor Pharmaceuticals
    • 18.2.2. Bristol-Myers Squibb
    • 18.2.3. Eisai
    • 18.2.4. F. Hoffmann-La Roche
    • 18.2.5. Merck
  • 18.3. Other and Possible Future Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Arbor Pharmaceuticals
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Strategy
    • 19.1.4. Recent Developments
    • 19.1.5. SWOT Analysis
  • 19.2. Bristol-Myers Squibb
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Key Product Offerings
    • 19.2.4. Revenue by Geography
    • 19.2.5. Business Strategy
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
  • 19.3. Eisai
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Comparison between Revenue, Operating Income, and Net Income
    • 19.3.4. Sales by Geography
    • 19.3.5. Business Strategy
    • 19.3.6. Key Information
    • 19.3.7. SWOT Analysis
  • 19.4. F. Hoffmann-La Roche
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Sales by Geography
    • 19.4.6. Business Strategy
    • 19.4.7. Key Information
    • 19.4.8. SWOT Analysis
  • 19.5. Merck
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Sales by Geography
    • 19.5.6. Business Strategy
    • 19.5.7. Key Developments
    • 19.5.8. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot of the Global Glioblastoma Multiforme Therapeutics Market
  • Exhibit 3: Global Glioblastoma Multiforme Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 4: Key Takeaways: Global Glioblastoma Multiforme Therapeutics Market
  • Exhibit 5: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Route of Administration
  • Exhibit 6: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Type of Molecule
  • Exhibit 7: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Geography 2014
  • Exhibit 8: Glioblastoma Multiforme Therapeutics Market in Americas 2014-2019 ($ millions)
  • Exhibit 9: Glioblastoma Multiforme Therapeutics Market in EMEA 2014-2019 ($ millions)
  • Exhibit 10: Glioblastoma Multiforme Therapeutics Market in APAC 2014-2019 ($ millions)
  • Exhibit 11: Global Glioblastoma Multiforme Therapeutics Market by Geography 2014-2019
  • Exhibit 12: Glioblastoma Multiforme: Pipeline Portfolio
  • Exhibit 13: Drug Candidates by Stage of Development (percentage)
  • Exhibit 14: Drivers of the Global Glioblastoma Multiforme Therapeutics Market
  • Exhibit 15: Challenges of the Global Glioblastoma Multiforme Therapeutics Market
  • Exhibit 16: Trends in the Global Glioblastoma Multiforme Therapeutics Market
  • Exhibit 17: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 18: Bristol-Myers Squibb Co.: Geographical Segmentation by Revenue 2013
  • Exhibit 19: Eisai: Comparison between Revenue, Operating Income, and Net Income 2011-2013 ($ billions)
  • Exhibit 20: Eisai: Sales by Geography 2013 ($ billions)
  • Exhibit 21: F. Hoffmann-La Roche: Business Segmentation2013
  • Exhibit 22: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 23: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 24: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 25: Merck: Business Segmentation by Revenue 2013
  • Exhibit 26: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
  • Exhibit 27: Merck: Sales by Geography 2013
Back to Top